Our mission: To develop new therapies for type 1 and type 2 diabetes
Fairbanks Pharmaceuticals is developing transformative diabetes therapies that address the underlying cause of diabetes: loss of insulin from beta cells.
Learn about Fairbanks Pharmaceuticals
- Read about the science behind our work.
- (March 2018) Fairbanks chosen as finalist in M2D2 $200K Challenge….Read more
- (March 2018) Positive niche assessment of Fairbanks’ potential in NIH-funded profile…Read more
- (September 2017) Fairbanks presented at the RESI Boston 2017 Innovation Challenge….Read more
- (September 2017) Fairbanks has successfully met all SBIR Phase I milestones and has submitted a Phase II application to focus on in vivo therapeutic benefits.
- (August 2017) Fairbanks was selected as a semifinalist and is competing to win a residency at MilliporeSigma’s Start-Up program at LabCentral…Read more
- (May 2017) Fairbanks presented its approach at the MassCONNECT Final Showcase to widespread pharma and private investor interest…Read more
- (March 2017) Fairbanks was selected to present at the Massachusetts Technology Transfer Center Early-Stage Life Center’s Technology Conference...Read more
- (February 2017) Fairbanks presented its introductory pitch to potential mentors at MassBio’s MassCONNECT 2017 kick-off meeting. MassCONNECT matches entrepreneurs and founders with seasoned life sciences professionals to catalyze and commercialize innovation…Read more
- (December 2016) Boehringer-Ingelheim Pharmaceuticals (BI) selected Fairbanks to compete for their Boston Innovation Prize…Read more
- (December 2016) Fairbanks Pharmaceuticals awarded a pilot grant from the UMass Office of the President’s Science and Technology Fund… Read more
- (Sept 2016) Fairbanks Pharmaceuticals selected as a semi-finalist in the Diabetes Innovation Challenge… Read more
- Background on CEO/CSO Alan Schneyer here and here.
- Sign up to the right to receive email updates with our latest news.